23andMe, a popular direct-to-consumer genetic testing company, made headlines after its CEO pledged to help reunite the more than 2,300 children separated from their parents at the U.S.’s southern ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million. The ...

Genetic testing company 23andMe laid off 100 employees on Jan. 23 due to decreasing sales of its direct-to-consumer DNA test kits, CNBC reports. The layoffs, which affect about 14 percent of the ...

Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year. The DNA testing company has faced major ...

(Reuters) -Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy ...

When we first wrote this article, it compared 23andMe and Ancestry. Since then, 23andMe has experienced a data breach, a subsequent lawsuit, board members' resignations and layoffs amidst financial ...

(Reuters) -Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services ...

Drugmaker Regeneron Pharmaceuticals is acquiring majority assets of bankrupt genetic testing firm 23andMe Holding for $256 million. The once-sizzling DNA-testing startup filed for bankruptcy in March, ...

23andMe, which sold saliva collection kits to consumers wanting insight into their genetic background, filed for bankruptcy in March 2025. The company has now agreed to sell its data bank to Regeneron ...